Search

CN-122004473-A - Lactobacillus plantarum BL-17 for relieving atopic dermatitis and application thereof

CN122004473ACN 122004473 ACN122004473 ACN 122004473ACN-122004473-A

Abstract

The invention provides a probiotic and prebiotic composition with the function of relieving atopic dermatitis and application thereof. In particular, the invention provides a composition containing different proportions of breast milk oligosaccharide and lactobacillus plantarum BL-17 and application thereof in relieving atopic dermatitis. The preservation number of the lactobacillus plantarum (Lactiplantibacillus plantarum) BL-17 is CCTCC NO: M20221596. The breast milk oligosaccharide comprises fucosyl oligosaccharide and neutral nonfucosyl oligosaccharide, and the relief of infant atopic dermatitis is characterized by significantly improving clinical pathological characteristics, including (1) significantly improving the skin swelling degree of mice, (2) significantly regulating the total IgE level in serum and the level of related cytokines IL-10 and the like, and (3) significantly regulating the bias imbalance of Th1/Th2 cells. The combination can be used as a functional food preparation for well relieving atopic dermatitis, especially atopic dermatitis caused by food allergy, and the invention provides a preparation method and application of the composition.

Inventors

  • LV WENQING
  • LIU SIBO
  • ZHAO MENGNA
  • LI BAILIANG

Assignees

  • 东北农业大学

Dates

Publication Date
20260512
Application Date
20260130

Claims (6)

  1. 1. A composition consisting of lactobacillus plantarum and breast milk oligosaccharide.
  2. 2. The composition of lactobacillus plantarum and breast milk oligosaccharide according to claim 1, wherein the lactobacillus plantarum is lactobacillus plantarum (Lactiplantibacillus plantarum) BL-17, and the ratio of the lactobacillus plantarum to the breast milk oligosaccharide is 1 x 10 6 CFU～1×10 10 CFU, 0.1 g-10 g.
  3. 3. The composition of claim 1 or 2 wherein the human milk oligosaccharide comprises one or more of 2 '-fucosyllactose, lactose-N-neotetraose, lactose-N-tetraose, lactofucopyranose II, 3' -fucosyllactose.
  4. 4. Use of a composition according to claim 1 or 2 for the preparation of a food, pharmaceutical or health product having the ability to effectively alleviate atopic dermatitis and its corresponding allergic symptoms.
  5. 5. A product for the prevention and/or treatment of atopic dermatitis, characterized in that it comprises lactobacillus plantarum BL-17.
  6. 6. A product for preventing and/or treating atopic dermatitis as claimed in claim 5, wherein the viable count of lactobacillus plantarum BL-17 in said product is not less than 1 x 10 6 CFU/mL.

Description

Lactobacillus plantarum BL-17 for relieving atopic dermatitis and application thereof Technical Field The invention relates to a probiotic and prebiotic composition capable of relieving atopic dermatitis and application thereof, in particular to a composition containing lactobacillus plantarum (Lactiplantibacillus plantarum) BL-17 and breast milk oligosaccharide, a related preparation method and application of the obtained composition. The composition can be applied to health food and health food, and belongs to the technical field of functional food. Background In infants, atopic dermatitis often occurs in the early stages of food allergy. Many infants with food allergies first develop eczema in the first months or years after birth, especially when exposed to certain food allergens (e.g., milk, eggs, nuts, etc.). These skin symptoms often manifest themselves at the beginning of food allergy, suggesting that the immune system may have begun to produce allergic reactions to certain foods. In recent years, the incidence of AD has gradually increased, affecting 10% to 20% of children, and persisting throughout adulthood in 1% to 3% of cases. In particular, the incidence rate in the infant population tends to rise year by year, and the clinical manifestations are dry skin itching, erythema exudation, subacute and chronic scaly skin. The pathogenesis of AD is heterogeneous and may be triggered by immune disorders, impaired epidermal barriers, and interactions between genes and environmental factors. Its main features include recurrent attacks, severe itching, immune system activation, TH2 cell expansion, early keratinocyte production of Thymic Stromal Lymphopoietin (TSLP), and chronic stage keratinocyte proliferation and apoptosis. Most patients with atopic dermatitis (about 80%) develop dermatitis in the form of immunoglobulin E (IgE) and have high serum IgE titers, which have been previously referred to as "exogenous" type human atopic dermatitis. At the end of the 20 Th century, researchers found that human beings had helper T cell Th1 and Th2 subsets. Th1 and Th2 are both differentiated from precursor CD4+ T cells. Many cytokines play an important role in Th1/Th2 differentiation. Related studies have shown that cells in peripheral blood of patients with atopic dermatitis are predominantly Th 2-type and that excessive IL-4 and IL-5 can be formed after stimulation by allergens, while the IFN-gamma content of Th1 secretion is drastically reduced. The primary event in allergic disease formation is the generation of allergen-specific cd4+ T cells. After the initial T cells are activated by APC, they differentiate into Th 2-type cells under the influence of the APC, while Th 1-type cells and IFN-gamma are inhibited. Effector Th2 cells produce IL-4, IL-5 and IL-13, which drive B cells to produce allergen specificity, promote eosinophil recruitment, mucus production, smooth muscle contraction and Th2 tissue homing. Treg has anti-inflammatory and autoimmune tolerance maintaining effects, while Th17 has a strong pro-inflammatory effect, treg/Th 17 balance plays an important role in maintaining autoimmune homeostasis of the body, and Treg/Th 17 imbalance is a key factor in the pathogenesis of many inflammatory and autoimmune diseases. Treg can induce B cell activation to produce homotype IgG4 through secretion of IL-10 and TGF-beta, and inhibit IgE production. In addition, tregs directly inhibit allergen-specific Th2 cell activation, thereby minimizing the production of key cytokines IL-13, IL-4, IL-5 during the allergic effect phase. Tregs can also suppress immune responses by directly inhibiting the activation of Th2 and Th17 cells, eosinophil and basophil activities, and can even prevent mast cell degranulation by intercellular contact. Early life is a critical stage in the development of allergy, and the immune system and intestinal flora of infants develop significantly, the first 1000 days after birth being considered as the critical period in which external factors (including nutrition) have the greatest influence on long-term immunity. Emerging studies indicate that HMOs found in breast milk may have potential therapeutic effects on infant allergy. HMO is composed of glucose, galactose, fucose, sialic acid and N-acetylglucosamine, which together constitute the third most abundant component in breast milk. To date, more than 200 structurally different HMOs have been identified. Related studies have shown that supplementing prebiotics early in life can significantly reduce the incidence of allergic disease in infants within two years of age. Based on the kind of HMO in breast milk, the synergistic effect between breast milk oligosaccharides is particularly important, especially in the aspects of regulation of intestinal microorganisms, immunopotentiation, anti-inflammation, anti-infection, neurodevelopment and the like. The interaction between the different oligosaccharides enables breast milk to provide a more